Alopexx
ALPXAlopexx is a clinical-stage biotechnology company developing broad-spectrum immune-mediated therapeutics designed to prevent and treat a wide range of bacterial, fungal, and parasitic infections.
Alopexx has filed an S-1 registration statement with the SEC and is not yet trading. Financial statements will appear here once it begins reporting as a public company.
S-1 Filings
Registration statements filed with the SEC ahead of the planned listing
Competitors
By market cap
By revenue growth
Profile
Alopexx is a clinical-stage biotechnology company developing broad-spectrum immune-mediated therapeutics designed to prevent and treat a wide range of bacterial, fungal, and parasitic infections. The company's platform targets Poly N-acetyl glucosamine (PNAG), a conserved surface molecule expressed by over 75 distinct microbial species, including antibiotic-resistant organisms. By targeting the PNAG backbone, Alopexx aims to provide a non-serotype-specific alternative to conventional vaccines and immediate-acting monoclonal antibody treatments.
Alopexx is a pioneer in targeting the conserved PNAG antigen to create the first broad-spectrum therapeutic antibody and a universal complementary vaccine for microbial infections.
Questions, answered.
- Who are Alopexx's competitors?
- Alopexx's key competitors include VaxCyte, Pfizer, Merck, and others. These companies compete in similar markets and product categories.
- Who does Alopexx partner with?
- Alopexx's notable partners include Brigham and Women’s Hospital, Biotech Consortia, Inc, Bharat Biotech International Limited, and others.
- Where is Alopexx headquartered?
- Alopexx is headquartered in United States of America.